hotspot -WSS

hotspot

author：fashion 2025-09-07 11:13:26 - browse：92

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： European regulators consider appeal over Amylyx ALS drug

entertainment

focus

WSS

PBMs drew scrutiny in House hearing — and so did pharma

Fed up with FDA, ALS advocates consider a take

House panel takes first step toward fixing drug shortages

Patients, doctors press FTC to beef up hospital merger scrutiny

Free Covid tests will again be offered to all U.S. households

There’s no way to know how good AI health technologies are

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Senate bill would ban some hospital facility fees

Guidelines to prevent youth baseball injuries need more muscle

There’s no way to know how good AI health technologies are

Medicare proposal to cover medical devices draws a mixed reaction

Covid’s new normal has set in amid another rise in cases

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A fraught question for the kids of Alzheimer’s: Is it coming for us?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Chamber of Commerce, DOJ clash in court over drug prices

leisure time

FDA weighs limits of animal data in assessing artificial wombs

Grad students accuse University of California of wage theft

A revolution in caring for preterm infants

Life sciences deals on track to hit lowest point since 2017

Information blocking fines are now fair game in health care

Senate bill would ban some hospital facility fees

entertainment

entertainment

focus

focus